Hatteras Venture Partners
Early-stage venture capital firm focused on building companies in transformative human medicine and disruptive healthcare technologies. Hatteras emphasizes a replicable, risk‑mitigated value-creation model and invests across biopharma, medical devices, diagnostics and healthcare IT from pre-clinical through early commercial stages. The firm is active nationally and participates as lead investor in rounds and in board-level engagement.
Hatteras Venture Partners
Services
Equity Investments (lead & syndicate)
Provides early-stage equity financing and frequently serves as a lead or syndicate investor in Series A and similar rounds (examples in sourced news: led an $8M Series A for 410 Medical; co-led an $11M Series A-2 for Artizan).
Board participation and governance support
Takes board seats and places partners on portfolio company boards as part of active post-investment governance (example: Hatteras partner Jeff Terrell joining 410 Medical board).
Company building / value-creation model
Operates a replicable value-creation model aimed at reducing investment risk and accelerating company development across therapeutic, device and health tech opportunities.
Syndicate and network access
Connects portfolio companies to co-investors, strategic partners and industry syndicates (examples show syndication with OSF Healthcare, Biohaven, Canaan, OrbiMed and others).
Equity Investments (lead & syndicate)
Provides early-stage equity financing and frequently serves as a lead or syndicate investor in Series A and similar rounds (examples in sourced news: led an $8M Series A for 410 Medical; co-led an $11M Series A-2 for Artizan).
Board participation and governance support
Takes board seats and places partners on portfolio company boards as part of active post-investment governance (example: Hatteras partner Jeff Terrell joining 410 Medical board).
Company building / value-creation model
Operates a replicable value-creation model aimed at reducing investment risk and accelerating company development across therapeutic, device and health tech opportunities.
Syndicate and network access
Connects portfolio companies to co-investors, strategic partners and industry syndicates (examples show syndication with OSF Healthcare, Biohaven, Canaan, OrbiMed and others).
Portfolio
Developing a versatile epigenetic editing platform using multiple effectors.
#Biopharma / Gene editing (epigenetic editing)
Developing an extracardiac, extravascular approach to cardiac pacing and defibrillation.
#Medical Device / Cardiac devices
Advance Care Planning solutions delivering improved outcomes, member experience and cost savings for plans.
#Healthcare IT / Services
AAV gene therapy company focused on reversing or preventing blindness.
#Biopharma / Gene therapy
Developing engineered AAV vectors that can evade neutralizing antibodies.
#Biopharma / Gene therapy
Developing small-molecule therapies to address unmet needs in oncology.
#Biopharma / Oncology
Developing a versatile epigenetic editing platform using multiple effectors.
#Biopharma / Gene editing (epigenetic editing)
Developing an extracardiac, extravascular approach to cardiac pacing and defibrillation.
#Medical Device / Cardiac devices
Advance Care Planning solutions delivering improved outcomes, member experience and cost savings for plans.
#Healthcare IT / Services
AAV gene therapy company focused on reversing or preventing blindness.
#Biopharma / Gene therapy
Developing engineered AAV vectors that can evade neutralizing antibodies.
#Biopharma / Gene therapy
Developing small-molecule therapies to address unmet needs in oncology.
#Biopharma / Oncology